BST Trade Alert
BST Trade Alert: July 18, 2014
July 18, 2014 Recommendation: Buy Rigel Pharmaceuticals (NASDAQ: RIGL) up to $3.30 About the Company: Rigel Pharmaceuticals is an exciting clinical-stage drug development company based in San Francisco, California. It’s focused on developing novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases as well as muscle disorders. Rigel currently has five product candidates in various […]
BST Trade Alert: June 20, 2014
June 20, 2014 Recommendation: Buy Regado Biosciences (NASDAQ: RGDO) up to $7.60 About the Company: Regado Biosciences is a fascinating biotech. It’s pioneering the development of actively controllable antithrombotic drug systems for cardiovascular indications. The company’s paired aptamer-active control agent technology is revolutionary. It’s designed to give physicians the ability to directly control the degree of antithrombotic […]
BST Trade Alert: May 29, 2014
May 29, 2014 Recommendation: Buy Xencor (NASDAQ: XNCR) up to $9.40 About the Company: Xencor is a clinical stage biotech developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. The company currently has six product candidates in clinical development internally and with large drug company partners. Each of these product […]
BST Trade Alert: April 30, 2014
April 30, 2014 Recommendation: Buy Exelixis (NASDAQ: EXEL) up to $3.75 About the Company: Exelixis is a small, development-stage biotech committed to developing small molecule therapies for the treatment of cancer. For purposes of this trade, we’re focusing on COMETRIQ® (cabozantinib), the company’s drug candidate for the treatment of metastatic castration-resistant prostate cancer. With that said, Exelixis […]
BST Trade Alert: April 8, 2014
April 8, 2014 Recommendation: Buy Catalyst Pharmaceutical Partners (NASDAQ: CPRX) up to $2.30 About the Company: Catalyst is a development-stage biotech focused on developing drugs for rare neuro-muscular and neurological diseases. It currently has three drugs in development for the treatment of Lambert-Easton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder. For purposes of this trade, we’re […]
BST Trade Alert: March 19, 2014
March 19, 2014 Recommendation: Buy Cerus (NASDAQ: CERS) up to $6.60 per share. About the Company: Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. INTERCEPT is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The company has worldwide rights to INTERCEPT for […]
BST Trade Alert: March 7, 2014
March 7, 2014 Recommendation: Buy Lpath (NASDAQ: LPTN) up to $5.30 per share. About the Company: Lpath is a fascinating biotech that has enormous potential. With its unique technology and scientific expertise, this tiny company is pioneering an entirely new approach to drug development. And if this new approach bears fruit, Lpath could become a new leader […]
BST Trade Alert: February 20, 2014
February 20, 2014 Recommendation: Buy Acasti Pharma (NASDAQ: ACST) up to $1.40 per share. About the Company: Acasti is a Canadian biotech focusing on the development of new therapies for dyslipidemia (abnormalities in blood lipids) and cardiovascular disorders. It was founded in 2002 and is a subsidiary of Neptune Technologies & Bioresources(NASDAQ: NEPT). The key to the company’s […]
BST Trade Alert: February 7, 2014
February 7, 2014 Recommendation: Buy Threshold Pharmaceuticals (NASDAQ: THLD) up to $4.80 per share. About the Company: Threshold is an exciting biotech focused on developing drugs that selectively target tumor cells for the treatment of patients living with cancer. The company’s leading drug candidate is TH-302, which is currently being studied in two phase 3 clinical trials […]
BST Trade Alert: January 22, 2014
January 22, 2014 Recommendation: Buy BioLineRx (NASDAQ: BLRX) up to $3.30 per share. About the Company: Today’s recommendation is one that many of you will recognize and remember fondly from last year. And for those of you who missed our initial trade in BLRX, you’re in for a real treat. Click here to read our prior trade alert […]
